AMEND Represents GenNETS Internationally
From 7-8 September, AMEND CEO, Jo Grey, represented our Genetic Neuroendocrine Tumour Syndrome (GenNETS) patient communities at the annual summit of the International Neuroendocrine Cancer Alliance in Sofia, Bulgaria.
Click here for more information